Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer, as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is based in Boston, Massachusetts.

Aura Biosciences, Inc.

Aura Energy ( ($AU:AEE) ) has provided an update. Aura Energy has announced the resignation of Chief Financial Officer Mark Somlyay, who will remai...

Aura Energy CFO to Depart as Tiris Uranium Project Timeline Remains on Track

Aura Energy ( ($AU:AEE) ) has provided an announcement. Aura Energy has removed a key technical risk at its Tiris uranium project by finalising a p...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AURA	$7.69	0.00%	1.05M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AURA	$7.69	0%	1.05M
3
4
5
6

AURA

Get Aura Biosciences, Inc. Data in Excel

Get Aura Biosciences, Inc. Data in Excel